Filing Details
- Accession Number:
- 0001193125-26-046663
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2026-02-11 16:30:06
- Reporting Period:
- 2026-02-09
- Filing Date:
- 2026-02-11
- Accepted Time:
- 2026-02-11 16:30:06
- SEC Url:
- Form 4 Filing
- 10b5-1 trading plan:
- Unchecked
The filer left the 10b5-1 checkbox unchecked. This is not proof that every trade was unplanned.
A 10b5-1 plan sets trading instructions in advance, so trades follow those instructions instead of a new decision at the time of each trade. The checkbox applies to the filing as a whole and does not identify every covered trade; see the footnotes for details. It reflects the filer's disclosure, not SEC approval of the plan. SEC Form 4 instructions.
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1778922 | Spyglass Pharma Inc. | SGP | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1746342 | Carmen Chang | 2855 Sand Hill Road Menlo Park CA 94025 | No | No | No | No |
Transaction Summary
| Purchased: | 937,500 shares | Avg. Price: $16.00 | Total Value: $15,000,000.00 |
| Number of Shares After Transactions: | 1,357,263 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2026-02-09 | 1,619,240 | Not reported | 1,619,240 | No | 4 | C | Indirect | See Note 2 |
| Common Stock | Acquisiton | 2026-02-09 | 1,370,168 | Not reported | 2,989,408 | No | 4 | C | Indirect | See Note 2 |
| Common Stock | Acquisiton | 2026-02-09 | 1,370,168 | Not reported | 4,359,576 | No | 4 | C | Indirect | See Note 2 |
| Common Stock | Acquisiton | 2026-02-09 | 737,962 | Not reported | 5,097,538 | No | 4 | C | Indirect | See Note 2 |
| Common Stock | Acquisiton | 2026-02-09 | 937,500 | $16.00 | 6,035,038 | No | 4 | P | Indirect | See Note 2 |
| Common Stock | Acquisiton | 2026-02-09 | 954,990 | Not reported | 954,990 | No | 4 | C | Indirect | See Note 3 |
| Common Stock | Acquisiton | 2026-02-09 | 402,273 | Not reported | 1,357,263 | No | 4 | C | Indirect | See Note 3 |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Note 2 |
| No | 4 | C | Indirect | See Note 2 |
| No | 4 | C | Indirect | See Note 2 |
| No | 4 | C | Indirect | See Note 2 |
| No | 4 | P | Indirect | See Note 2 |
| No | 4 | C | Indirect | See Note 3 |
| No | 4 | C | Indirect | See Note 3 |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Preferred Stock | Disposition | 2026-02-09 | 1,619,240 | $0.00 | 1,619,240 | $0.00 |
| Common Stock | Series C-1 Preferred Stock | Disposition | 2026-02-09 | 1,370,168 | $0.00 | 1,370,168 | $0.00 |
| Common Stock | Series C-2 Preferred Stock | Disposition | 2026-02-09 | 1,370,168 | $0.00 | 1,370,168 | $0.00 |
| Common Stock | Series D Preferred Stock | Disposition | 2026-02-09 | 737,962 | $0.00 | 737,962 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2026-02-09 | 954,990 | $0.00 | 954,990 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2026-02-09 | 402,273 | $0.00 | 402,273 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.
- The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.
- The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.